GLP-1 receptor agonists have transformed metabolic disease.
In neurodegeneration, results are promising but mixed.
We review mechanistic data, trial evidence, and the need for biologically informed patient stratification across PD, AD and related disorders.
Our @JCIJournal Review: jci.org/articles/view/194745
@foltynie @LabGandhi @UCLIoN @TheCrick @ScienceofPD
Dilan Athauda retweeted
Is insulin resistance an early modifying factor for the later occurrence of Parkinson's disease? All the talk of GLP-1 diabetes drugs begs the question. Alise Zagare and colleagues write about their work in the latest issue of @MDJ_Journal.
Key Points:
- The authors point to studies showing that central insulin resistance might have big role in Parkinson's.
- Why does it emerge?
- They looked at insulin resistance and its role in GBA1 mutations.
- They used mini-brains in a dish (organoids).
- Insulin signaling pathway genes were dysregulated.
- They rescued some of the effect with a knockdown of FOXO1.
- They point to using the anti-diabetic drug Pioglitazone in GBA-PD.
My take: This is an interesting study and a fascinating question. Pioglitazone failed a clinical trial for Parkinson's disease in general; however maybe it needs to be personalized for those only w/GBA Parkinson's. It is really hard to pull off because of the ~10% penetrance of GBA, the difficulty in recruiting folks, and the heterogeneity of presentations. It will be interesting to see if the science holds up in human. Very cool! Are we getting closer to personalization of therapies?
movementdisorders.onlinelibr… #Parkinson
Dilan Athauda retweeted
Interesting @biorxivpreprint from @DilanAthauda @LabGandhi & colleagues reports GLP-1R agonist exenatide restores insulin signalling (via restoration of Akt & suppression of MAPK pathways) & reverses synucleinopathy toxicity; Implications for #Parkinsons?
biorxiv.org/content/10.1101/…
Dilan Athauda retweeted
Identification of target cell types and mechanisms through which GLP-1R agonism may represent a disease modifying strategy in synucleinopathies #Parkinsons disease biorxiv.org/content/10.1101/… #insulin resistance
Dilan Athauda retweeted
Machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, reports a study published in @NatMachIntell. go.nature.com/3qDl3yO
Dilan Athauda retweeted
A great collaborative effort from @LabGandhi @GurvirVirdi @DilanAthauda @MineeChoi @faculty_ai @MathewHHorrocks @EdBiophysics
Dilan Athauda retweeted
The @LabGandhi team took part in an intensive coding course when the pandemic disrupted their research – and now they’ve published work with @faculty_ai showing that computer models can classify types of Parkinson’s from images of stem cells 🧠
@UCLIoN crick.ac.uk/news/2023-08-10_…
Dilan Athauda retweeted
New research presents MAPKAPK2 as a potential early diagnostic biomarker of diseases associated with the aggregation of α-synuclein, such as #Parkinsons;
nature.com/articles/s41531-0…
Dilan Athauda retweeted
New paper from @GurvirVirdi @MineeChoi @LabGandhi & collaborators uses hiPSCs to delve into the "temporal sequence of SNCA-induced pathophysiological events in order to discover early, & likely causative, events" in #Parkinsons; A lot to unpack here!
nature.com/articles/s41531-0…
Dilan Athauda retweeted
🎉Our latest paper from @GurvirVirdi @LabGandhi highlighting a new mDA neuron #iPSC #Parkinsons model with protein aggregation and calcium dysregulation molecular hallmarks. Congratulations team!! @ASAP_Research
#asynuclein #openscience #collaboration
nature.com/articles/s41531-0…
Dilan Athauda retweeted
📢Preprint alert 🚨
Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in human midbrain dopaminergic neurons. Go and check it out!
@GurvirVirdi @LabGandhi @MineeChoi @evansrjames @wernick_anna
biorxiv.org/content/10.1101/…
Dilan Athauda retweeted
JOB ALERT
We have a new Research Technician role available with @LabGandhi
To apply
atsv7.wcn.co.uk/search_engin…
Dilan Athauda retweeted
Ooooh, look at that:
@MicheleTagliati & colleagues have made a preprint of results of the Phase II, randomized, double-blinded, placebo-controlled clinical trial of Liraglutide in #Parkinsons available - Study funded by @CureParkinsonsT
papers.ssrn.com/sol3/papers.…
Dilan Athauda retweeted
A brilliant meeting for ACORD fellows yesterday, chaired by @suvankarpal at @MRCCTU . A lot of exciting novel trial-related work going on across neurodegenerative diseases. And always incredible to hear the STAMPEDE trial success story from @MaxParmarMRCUCL . – at Islington, London
Dilan Athauda retweeted
Our latest work is finally out!! Congratulations to a fantastic team of collaborators @LabGandhi @KlenermanLab @MathewHHorrocks @KunathLab @EM_STP and our labs @UCLIoN and @TheCrick and huge thanks to our funders @The_MRC and @ASAP_Research nature.com/articles/s41593-0…
Our new paper in @MDJ_Journal, Type 2 diabetes is associated with faster progression of motor and non-motor symptoms in #Parkinsons..thank you to all the participants in PRoBaND study and the clinical consortium! @CureParkinsonsT @ParkinsonsUK
tinyurl.com/5n7pnpu7
An exciting opportunity for any post-docs interested in exploring metabolism & neurodegeneration to work with me in the Gandhi Lab - happy to chat if interested (closing date 19th Jan)
@CureParkinsonsT @UKEVSoc @TheCrick @LabGandhi
Great opportunity for a post-doctoral research fellow at @TheCrick @LabGandhi
The project utilizes #ExtracellularVesicles to understand the pathophysiological basis of the interaction between metabolism and neurodegeneration. Reach out if interested!
atsv7.wcn.co.uk/search_engin…
Dilan Athauda retweeted
Great opportunity for a post-doctoral research fellow at @TheCrick @LabGandhi
The project utilizes #ExtracellularVesicles to understand the pathophysiological basis of the interaction between metabolism and neurodegeneration. Reach out if interested!
atsv7.wcn.co.uk/search_engin…





























